Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHLNASDAQ:ALLONASDAQ:ATXSNASDAQ:AVIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHLAchilles Therapeutics$1.48$1.48$0.63▼$1.51$60.83M1.25606,389 shsN/AALLOAllogene Therapeutics$1.09-1.8%$1.42$0.86▼$3.78$238.42M0.63.32 million shs1.08 million shsATXSAstria Therapeutics$4.08+4.1%$4.80$3.56▼$12.92$221.22M0.45372,382 shs943,267 shsAVIRAtea Pharmaceuticals$2.85+1.4%$2.89$2.46▼$4.15$243.90M0.17307,252 shs343,023 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHLAchilles Therapeutics0.00%0.00%0.00%+7.25%+64.44%ALLOAllogene Therapeutics-1.80%0.00%-31.45%-49.77%-59.02%ATXSAstria Therapeutics+4.08%+2.26%-11.69%-40.09%-55.21%AVIRAtea Pharmaceuticals+1.42%+10.04%-0.70%-7.77%-25.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACHLAchilles TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AALLOAllogene Therapeutics3.5799 of 5 stars4.53.00.00.02.33.30.6ATXSAstria Therapeutics1.9778 of 5 stars3.63.00.00.01.61.70.0AVIRAtea Pharmaceuticals2.4093 of 5 stars3.32.00.00.01.92.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHLAchilles Therapeutics 0.00N/AN/AN/AALLOAllogene Therapeutics 2.90Moderate Buy$8.44674.72% UpsideATXSAstria Therapeutics 3.25Buy$30.00635.29% UpsideAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.00110.53% UpsideCurrent Analyst Ratings BreakdownLatest ACHL, AVIR, ATXS, and ALLO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ALLOAllogene TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.005/14/2025ALLOAllogene TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$9.00 ➝ $7.005/14/2025ALLOAllogene TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $10.005/14/2025ALLOAllogene TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.005/14/2025ALLOAllogene TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.005/14/2025ALLOAllogene TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$12.00 ➝ $9.005/14/2025ALLOAllogene TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/14/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$47.00 ➝ $47.004/29/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$47.004/11/2025AVIRAtea PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$6.20 ➝ $6.00(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHLAchilles TherapeuticsN/AN/AN/AN/A$3.49 per shareN/AALLOAllogene Therapeutics$22K10,837.13N/AN/A$3.04 per share0.36ATXSAstria TherapeuticsN/AN/AN/AN/A$3.33 per shareN/AAVIRAtea PharmaceuticalsN/AN/AN/AN/A$6.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHLAchilles Therapeutics-$69.67M-$1.65N/AN/AN/AN/A-54.45%-47.68%N/AALLOAllogene Therapeutics-$327.27M-$1.23N/AN/AN/AN/A-52.13%-41.29%8/6/2025 (Estimated)ATXSAstria Therapeutics-$72.89M-$1.87N/AN/AN/AN/A-43.58%-29.36%8/11/2025 (Estimated)AVIRAtea Pharmaceuticals-$135.96M-$1.65N/AN/AN/AN/A-34.90%-32.38%8/6/2025 (Estimated)Latest ACHL, AVIR, ATXS, and ALLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ALLOAllogene Therapeutics-$0.28-$0.28N/A-$0.28$0.00 millionN/A5/13/2025Q1 2025ATXSAstria Therapeutics-$0.48-$0.58-$0.10-$0.58N/AN/A5/12/2025Q1 2025AVIRAtea Pharmaceuticals-$0.56-$0.40+$0.16-$0.40N/AN/A3/13/2025Q4 2024ALLOAllogene Therapeutics-$0.34-$0.28+$0.06-$0.28$0.01 millionN/A3/11/2025Q4 2024ATXSAstria Therapeutics-$0.45-$0.44+$0.01-$0.44N/AN/A3/6/2025Q4 2024AVIRAtea Pharmaceuticals-$0.35-$0.40-$0.05-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHLAchilles TherapeuticsN/AN/AN/AN/AN/AALLOAllogene TherapeuticsN/AN/AN/AN/AN/AATXSAstria TherapeuticsN/AN/AN/AN/AN/AAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHLAchilles TherapeuticsN/A6.046.04ALLOAllogene TherapeuticsN/A9.359.35ATXSAstria TherapeuticsN/A22.3822.38AVIRAtea PharmaceuticalsN/A19.3319.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHLAchilles Therapeutics56.38%ALLOAllogene Therapeutics83.63%ATXSAstria Therapeutics98.98%AVIRAtea Pharmaceuticals86.67%Insider OwnershipCompanyInsider OwnershipACHLAchilles Therapeutics5.38%ALLOAllogene Therapeutics13.20%ATXSAstria Therapeutics2.90%AVIRAtea Pharmaceuticals18.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHLAchilles Therapeutics25041.10 million38.89 millionNot OptionableALLOAllogene Therapeutics310218.73 million158.72 millionOptionableATXSAstria Therapeutics3056.43 million54.80 millionOptionableAVIRAtea Pharmaceuticals7085.58 million69.43 millionOptionableACHL, AVIR, ATXS, and ALLO HeadlinesRecent News About These CompaniesAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Holdings Increased by Tang Capital Management LLCMay 20 at 6:24 AM | marketbeat.comJacobs Levy Equity Management Inc. Lowers Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)May 19, 2025 | marketbeat.comWilliam Blair Issues Pessimistic Estimate for AVIR EarningsMay 17, 2025 | americanbankingnews.comNewtyn Management LLC Purchases 200,000 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)May 16, 2025 | marketbeat.comDimensional Fund Advisors LP Has $3.27 Million Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)May 16, 2025 | marketbeat.comAtea Pharmaceuticals (NASDAQ:AVIR) Issues Earnings Results, Beats Expectations By $0.01 EPSMay 14, 2025 | marketbeat.comAtea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comAtea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on MondayMay 7, 2025 | marketbeat.comAtea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025May 7, 2025 | globenewswire.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Stake Lessened by Almitas Capital LLCMay 4, 2025 | marketbeat.comAtea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025May 1, 2025 | globenewswire.comJPMorgan Chase & Co. Buys 314,015 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)April 28, 2025 | marketbeat.comRBF Capital LLC Has $183,000 Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)April 26, 2025 | marketbeat.comAtea Pharmaceuticals announces results from phase 2 study of bemnifosbuvirApril 24, 2025 | markets.businessinsider.comAtea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025April 23, 2025 | globenewswire.comWhy Atea Pharmaceuticals, Inc.’s (AVIR) Stock Is Up 5.33%April 18, 2025 | aaii.comAtea Pharmaceuticals says strategic alternatives process ‘ongoing’April 17, 2025 | markets.businessinsider.comAtea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase ProgramApril 17, 2025 | globenewswire.comMorgan Stanley Remains a Hold on Atea Pharmaceuticals (AVIR)April 13, 2025 | markets.businessinsider.comAtea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 studyApril 9, 2025 | msn.comAtea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C VirusApril 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACHL, AVIR, ATXS, and ALLO Company DescriptionsAchilles Therapeutics NASDAQ:ACHL$1.48 0.00 (0.00%) As of 03/26/2025Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.Allogene Therapeutics NASDAQ:ALLO$1.09 -0.02 (-1.80%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$1.10 +0.01 (+1.38%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Astria Therapeutics NASDAQ:ATXS$4.08 +0.16 (+4.08%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$4.08 +0.00 (+0.12%) As of 05/22/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.Atea Pharmaceuticals NASDAQ:AVIR$2.85 +0.04 (+1.42%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$2.90 +0.05 (+1.93%) As of 05/22/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1 Cathie Wood Just Bought a New Stake in Taiwan Semiconductor Stock Super Micro Computer Stock Clears New Path Higher on Saudi Orders Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith? Why Carnival Could Be the Ultimate Non-Tech Growth Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
